top of page

Measuring health via ancestral genes

Our Discovery: Endogenous Ancestral Nucleotide Sequences (EANS)

DNA

Analogy: "Having the manual"

Utility: Which disease risk group am I in?

Total RNA

"Reading the manual"

Do I have general inflammation?

EANS RNA

"Reading the relevant parts of the manual"

Which specific genomic hotspots are activated?

We measure health through AI Genomics

Our science is based on the observation that when specific regions of our genomes are activated, the disease process is activated. These regions are genetic sequences that our ancestors have accumulated over generations.

These endogenous ancestral nucleotide sequences, EANS, are the cause of many diseases. And we have discovered a method to measure them. The measurement of EANS enables three use cases: early genomic health screening, differential EANS expression, and tracking individual genomic health over time.

 

Our AI Genomics technology behind these measurements is based on our machine learning algorithms that use data filtered through our proprietary panels of different EANS categories.

Partnering with U Michigan on EANS professorships

$5M legacy gift awarded to the University of Michigan Department of Microbiology and Immunology for virology research.

This gift will accelerate discovery and innovation in virus-genome interactions in pursuit of life-changing therapies.

Peer-reviewed publications
 

FBB's CEO built a test based on ancestral genes to detect asymptomatic silent carriers: "Urine Antibody Tests: New Insights into the Dynamics of HIV-1 Infection"

FBB's CEO published the landmark review of the role of a subgroup of EANS in human disease: "Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease"

Co-infection by lactic dehydrogenase virus and C-type retrovirus elicits neurological disease

Chronically Expressed Blood-Borne Endogenous Ancestral Nucleotide Sequences RNA of Patients with Multiple Sclerosis, Alzheimer’s, or Parkinson’s Disease are Biomarkers for Differential Diagnosis and Monitoring

Newly Discovered Blood RNA Biomarkers in Relapsing Remitting Multiple Sclerosis Patients are Expressed Higher than in Patients with Alzheimer’s Disease, Parkinson’s Disease, or Amyotrophic Lateral Sclerosis

RNA Differential Expression In Serial Blood Samples Of Relapsing Remitting Multiple Sclerosis Patients Correlates With Clinically Reported Flares

Publications by FBB Biomed:

Publications related to EANS:

bottom of page